4basebio (LON:4BB) Announces Earnings Results

4basebio (LON:4BB) issued its earnings results on Monday. The company reported GBX (0.57) EPS for the quarter, Digital Look Earnings reports.

4basebio Price Performance

Shares of LON 4BB traded down GBX 2.70 during trading on Tuesday, hitting GBX 559.80. The company had a trading volume of 261 shares, compared to its average volume of 1,353. The company has a market cap of £86.69 million, a P/E ratio of -5.14 and a beta of 1.09. The company has a debt-to-equity ratio of 201.47, a quick ratio of 3.52 and a current ratio of 2.73. The business’s 50-day moving average is GBX 511.05 and its 200 day moving average is GBX 510.01. 4basebio has a 52 week low of GBX 420 and a 52 week high of GBX 820.

Analyst Ratings Changes

Separately, Royal Bank Of Canada cut their price target on 4basebio from GBX 1,600 to GBX 1,400 and set an “outperform” rating on the stock in a report on Monday, June 15th. One analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of GBX 1,400.

4basebio Company Profile

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.